Endocannabinoid system--a novel target for cardiometabolic risk

Area of Science:

• Neuroscience
• Pharmacology
• Metabolic Disorders

Background:

• The endocannabinoid system (EC) significantly influences appetite and related behaviors.
• Dysregulation of the EC system is implicated in obesity, substance abuse, and neurological disorders.

Purpose of the Study:

• To explore the therapeutic potential of modulating the EC system for conditions characterized by excessive appetite.
• To highlight the role of cannabinoid receptor antagonists in treating metabolic and neurological disorders.

Main Methods:

• Rational drug discovery was employed to design cannabinoid receptor antagonists.
• Focus on selective CB1 receptor antagonists/inverse agonists.

Main Results:

• Rimonabant, a selective CB1 antagonist, is approved in the EU and India for obesity treatment.
• Rimonabant is under regulatory review in the US for obesity and cardiometabolic risk.

Conclusions:

• Attenuating EC system activity presents a viable therapeutic strategy for obesity, addiction, and CNS disorders.
• Selective CB1 receptor antagonists represent a promising class of drugs for metabolic and neurological conditions.